Biotech to See 10.1% Sales CAGR Between 2005 and 2011 According to New Report.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c52507) has announced the addition of Datamonitor's new report: The Pharmaceutical Company Outlook to 2011: Financial and Strategic Analysis of the Sales Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech to their offering. Based on an analysis of 46 companies and 1,000+ products, we forecast that pharmaceutical industry ethical sales will increase at a modest 4.9% CAGR CAGR See: Compound Annual Growth Rate 200511. However, behind this industry average figure there are strategic segments of the market that offer double-digit growth rates Growth Rates The compounded annualized rate of growth of a company's revenues, earnings, dividends, or other figures. Notes: Remember, historically high growth rates don't always mean a high rate of growth looking into the future. through barriers against generic competition and the opportunity for aggressive indication broadening. Scope of this title: * Financial and Strategic Analysis of the Sales Outlook to 2011 for Big Pharma, Mid Pharma, Japan Pharma and Biotech * Quantitative analysis Quantitative Analysis A security analysis that uses financial information derived from company annual reports and income statements to evaluate an investment decision. Notes: of the revenue balance of launches and expiries for each peer set member to 2011 * Assessment of current and forecast 2011 therapeutic focus and product type focus for each peer set member * 2002-2006 operating cost and EBIT EBIT See: Earnings Before Interest and Taxes EBIT See earnings before interest and taxes (EBIT). margin analysis for each peer set member Highlights of this title: * Faced with failing growth, Big Pharma is expected to pursue strategic options including operational cost efficiencies, M&A with other Big Pharma companies, biotech, Mid Pharma CNS See Continuous net settlement. CNS See continuous net settlement (CNS). players and/or generics manufacturers and acquisitional moves outside of pharma space to increase presence in medical devices, diagnostics and consumer healthcare. * Biotech will be the fastest growing peer set with a 10.1% sales CAGR 2005-11. Biotech is almost totally insulated in·su·late tr.v. in·su·lat·ed, in·su·lat·ing, in·su·lates 1. To cause to be in a detached or isolated position. See Synonyms at isolate. 2. from generic threat because (1) biotech portfolios are often too young to contain expired products and (2) even if products have expired, the predominantly biologic nature of biotech portfolios is a major barrier to generic entry. * The fastest growing Japanese companies This is a list of companies from Japan. Note that 株式会社 can be (and frequently is) read both kabushiki kaisha and kabushiki gaisha (with or without a hyphen). See that article for more details. (such as Daiichi-Sankyo and Astellas) will receive the majority of their growth from expanding sales of already marketed products whereas the slowest growing companies (such as Takeda and Eisai) are burdened with heavy sales declines from patent expiries particularly in the gastrointestinal therapy area. Reasons to order your copy: * Understand the strategic motives behind the recent wave of Big Pharma acquisitions of monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing companies * Identify the rare examples of promising high growth CNS products located in the Mid Pharma peer set * Learn how biotech faces slowing growth momentum due to second generation biologics cannibalizing sales of first generation predecessor products. For more information visit http://www.researchandmarkets.com/reports/c52507 Source: Datamonitor |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion